Scarica l'app Stockscreener
13.13
0.15%
0.02
Dopo l'orario di chiusura:
13.21
0.08
+0.61%
Precedente Chiudi:
$13.11
Aprire:
$13.1
Volume 24 ore:
1.17M
Relative Volume:
0.59
Capitalizzazione di mercato:
$789.74M
Reddito:
$439.00K
Utile/perdita netta:
$-105.64M
Rapporto P/E:
-7.2944
EPS:
-1.8
Flusso di cassa netto:
$-60.70M
1 W Prestazione:
+7.80%
1M Prestazione:
-6.41%
6M Prestazione:
-45.90%
1 anno Prestazione:
-64.30%
Intervallo 1D:
$13.02
$13.48
Intervallo di 1 settimana:
$12.42
$13.61
Portata 52W:
$12.12
$38.42
Janux Therapeutics Inc Stock (JANX) Company Profile
Nome
Janux Therapeutics Inc
Settore
Industria
Telefono
(858) 751-4493
Indirizzo
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
13.13 | 788.54M | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-10 | Iniziato | Stifel | Buy |
| 2025-09-10 | Iniziato | Truist | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-07-11 | Iniziato | Raymond James | Outperform |
| 2024-12-03 | Reiterato | BTIG Research | Buy |
| 2024-12-03 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-22 | Iniziato | Leerink Partners | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-05-30 | Iniziato | Scotiabank | Sector Perform |
| 2024-03-21 | Iniziato | BTIG Research | Buy |
| 2024-03-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Iniziato | Wedbush | Outperform |
| 2022-11-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Janux Therapeutics Inc Borsa (JANX) Ultime notizie
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring a Potential 379% Upside in Biotech Innovations - DirectorsTalk Interviews
What is Janux Therapeutics Inc.’s valuation compared to sectorEarnings Overview Summary & Fast Momentum Entry Tips - mfd.ru
Breakout Watch: What is Janux Therapeutics Incs debt to equity ratioDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Bristol Myers Squibb Expands RNA And Cell Therapy Pipeline As Valuation Lags - Yahoo! Finance Canada
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week LowShould You Sell? - MarketBeat
Janux Therapeutics, Inc. (JANX) faces platform risk amid lack of durability data on JANX007 - MSN
(JANX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High? - Yahoo Finance UK
Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007 - Insider Monkey
Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX) - Yahoo Finance
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Bristol-Myers Squibb Expands Cancer Efforts With New AI And Drug Deals - Yahoo Finance UK
Why is Janux Therapeutics Inc. stock going downPortfolio Value Report & Weekly High Conviction Trade Ideas - mfd.ru
Will BMY's Oncology Collaborations Drive Its Next Growth Phase? - The Globe and Mail
Janux Therapeutics Repeat Insider Selling Not A Positive Indicator - simplywall.st
Eikon Therapeutics targets $908 million valuation in US IPO - Yahoo Finance
Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy - Yahoo Finance
Janux Therapeutics appoints William Go as new chief medical officer By Investing.com - Investing.com Nigeria
Janux Therapeutics (NASDAQ:JANX) Shares Gap DownShould You Sell? - MarketBeat
Janux Therapeutics Taps Dr. William Go as Chief Medical Officer - Contract Pharma
Janux Therapeutics appoints William Go as new chief medical officer - Investing.com
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - ChartMill
Bristol Myers inks licensing deal with Janux for cancer therapy - MSN
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion (BMY) - Seeking Alpha
BTIG Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100 - 富途牛牛
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
A Look At Bristol Myers Squibb (BMY) Valuation After New Microsoft AI Pact And Camzyos Trial Results - Yahoo Finance
Price-Driven Insight from (JANX) for Rule-Based Strategy - Stock Traders Daily
JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Finviz
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - ET Pharma
Janux Therapeutics Inks Global Oncology Collaboration With BMS - TipRanks
Janux Therapeutics Signs Exclusive License and Collaboration Agreement With Bristol-Myers Squibb - TradingView
Janux Therapeutics (NASDAQ:JANX) Sees Strong Trading VolumeHere's Why - MarketBeat
Janux Therapeutics Pairs With BMS on Novel Tumor-Activated Therapeutic - Contract Pharma
Key facts: Bristol Myers Squibb signs $850M deal with Janux; partners with Microsoft for AI - TradingView
BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy - MedCity News
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
BMS bets on Janux’s novel solid tumour therapy through $850m deal - Yahoo Finance
Janux Therapeutics, Inc. Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop A Novel Tumor-Activated Therapeutic for Solid Tumors - marketscreener.com
Bristol Myers buys into Janux’s ‘masked’ T cell engagers - BioPharma Dive
Janux, Bristol Myers Squibb partner on tumor-activated therapy By Investing.com - Investing.com Canada
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - BioSpace
Janux stock rises after Bristol Myers Squibb collaboration deal By Investing.com - Investing.com UK
Janux stock rises after Bristol Myers Squibb collaboration deal - Investing.com
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments - BioSpace
Janux Therapeutics Secures Exclusive License Agreement with Bristol Myers Squibb, Potential Earnings Up to $800 Million - Intellectia AI
Bristol Myers (BMY) Partners with Janux Therapeutics on Cancer T - GuruFocus
Janux Therapeutics Inc Azioni (JANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):